Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
| Status: | Recruiting |
|---|---|
| Conditions: | Skin Cancer, Skin and Soft Tissue Infections, Infectious Disease, Infectious Disease |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Immunology / Infectious Diseases, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/17/2019 |
| Start Date: | November 15, 2018 |
| End Date: | June 30, 2019 |
| Contact: | Study Director |
| Email: | info@micurx.com |
| Phone: | 510-782-2022 |
A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure Infection
The purpose of this study is to determine whether contezolid acefosamil is as safe and
effective as linezolid in the treatment of adult patients with acute bacterial skin and skin
structure infections
effective as linezolid in the treatment of adult patients with acute bacterial skin and skin
structure infections
Inclusion Criteria:
- Patients with systemic signs of infection diagnosed with acute bacterial skin and skin
structure infection (ABSSSI)
- Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections
Exclusion Criteria:
- Uncomplicated skin infections
- Severe sepsis or septic shock
- ABSSSI solely due to gram-negative pathogens
- Prior systemic antibiotics within 96 hours of randomization
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials